Series Editor
George Y. Wu
University of Connecticut Health Center, Farmington, CT, USA

For other titles published in this series, go to
http://www.springer.com/series/7672
I would like to dedicate this book to the memory of my brother Andy, who dedicated his life to help those less fortunate than us all.
Preface

One decade has passed since I first set “pen to paper” to launch the first edition of Inflammatory Bowel Disease: Diagnosis and Therapeutics, and yet, it seems that an entire lifetime of progress has been made in the world of “IBD” since that time. We were in the infancy of the biologic revolution; the first IBD gene was identified, and we were just beginning to get a hint that these diseases were sprouting up in people, and in places, where they formerly had never been seen.

Simultaneously, the world was changing as well. The economic roller coaster was perhaps felt strongest in the United States, spurring heated debate over the structure and function of the entire healthcare system, as the economic realities of soaring costs of care in our aging population finally were put on the front burner of political discourse and policy. The terms “cost-effectiveness” and “evidence-based medicine” have suddenly moved from the pages of the medical economic journals to the speeches of politicians, as a new focus on the delivery of health care was born.

The research community expanded further into novel pharmaceuticals, biological agents, and novel approaches of targeting the immune system. Stem cell research held forth the promise of true breakthroughs in our entire approach to disease management, while patient compliance deficiencies have spurred a quest for simpler, better accepted therapies.

This was also the “decade of the patient.” Expansion of patient privacy regulations, empowerment of patients through instantly available information (or misinformation) on the Internet, and “direct-to-consumer” marketing of prescription drugs introduced an entirely new two-way communication between the givers and receivers of health care. An unbridled “alternative” health care industry has developed into a very big business, and there is much interest among patients, and even practitioners, about these products. Unfortunately, the lack of regulation (and lack of interest among legislatures to close this legal loophole) leaves the public at the mercy of the unproven, both in terms of product efficacy and safety.

So what does this second version of Inflammatory Bowel Disease: Diagnosis and Therapeutics, Second Edition have to offer for its readers? The chapters contained in this book truly bring one to the cutting edge in IBD: the changing epidemiology, the explosion in genetics, and new understanding of the pathogenesis of disease.
Exciting new therapies are explored in both adults and children; updates on optimal uses of currently available therapies, alternative approaches to care, and novel surgical procedures detailed. The reader is then plunged into a truly evolving world of new radiographic, endoscopic, and other techniques utilized in the diagnosis of these diseases and their complications, with fascinating images readily available by today’s technology. A new twist in this edition is the “pathology slide show,” which clearly shows the major findings and differential diagnoses that one will encounter with patients with suspected or confirmed IBD. Rounding out the tour are new findings in the diagnosis and prevention of colorectal cancer in IBD, economic challenges in the new world, as well as issues specific to women with IBD and those with fecal diversions.

The end result is a culmination of 10 more years of knowledge, a decade of more advances, and the launch pad for the next waves of knowledge in the study and care of patients with IBD. It is my great hope that you as the reader find this second edition of Inflammatory Bowel Disease to be as rewarding as it has been to me to have the honor serve once again as editor.

Chicago
July 2010
## Contents

1. The Influence of Twentieth-Century Biomedical Thought on the Origins of Inflammatory Bowel Disease Therapy .......................... 1  
   Joseph B. Kirsner

2. The Changing Epidemiology of IBD .................................................... 17  
   Anders Ekbom

3. Recent Advances in the Genetics of IBD........................................... 27  
   Russell D. Cohen

4. New Paradigms in the Pathogenesis of IBD ...................................... 41  
   Giorgos Bamias, Theresa Pizarro, and Fabio Cominelli

5. State of the Art Medical Treatment of the Adult Patient with IBD: The Mesalamine-Based Therapies ........................................ 59  
   L. Campbell Levy and Corey A. Siegel

6. State of the Art Medical Treatment of the Adult Patient with IBD: Modern Use of Corticosteroids ....................................... 73  
   Wojciech Blonski, David Kotlyar, and Gary R. Lichtenstein

7. State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators ......................................................... 93  
   Dana Moffatt and Charles N. Bernstein

8. State-of-the-Art Medical Treatment of the Adult Patient with IBD: The Biological Therapies ................................................. 111  
   Stephen B. Hanauer

9. Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD ..................................................................................... 123  
   Richard N. Fedorak, Levinus A. Dieleman, and Karen L. Madsen
10 State-of-the-Art Management of the Pediatric IBD Patient .......... 151
Marla Dubinsky

11 Innovations in the Surgical Treatment of Inflammatory
Bowel Disease ................................................................. 165
Roger Hurst

12 Clinical Utility of Serological Markers and Thiopurine
Drug Monitoring in IBD: An Evidence-Based Review ............. 177
Raja Tamaz and Ernest G. Seidman

13 Caring for Women with Inflammatory Bowel Disease ............ 195
Sunanda Kane and Rebecca Kowalczyk

14 Novel Radiographic Techniques in IBD Patients .................. 207
V. Anik Sahni and Koenraad J. Mortele

15 Novel Techniques in the Diagnosis of Inflammatory
Bowel Disease ................................................................. 231
Shabana F. Pasha and Jonathan A. Leighton

16 Inflammatory Bowel Disease Pathology Slideshow ............... 255
Christopher R. Weber

17 New Findings in the Diagnosis and Prevention of Colorectal
Cancer in IBD .................................................................. 265
David T. Rubin and Jami A. Rothe

18 Managing the Patient with a Fecal Diversion ...................... 281
Janice C. Colwell

19 The New Economic Reality in the World of IBD .................... 295
Nanda Venu and Russell D. Cohen

Index .................................................................................. 315
Contributors

Giorgos Bamias, MD  Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, MC 2100, 5841 S. Maryland Avenue, Chicago, IL 60637, USA

Charles N. Bernstein, MD  Section of Gastroenterology, University of Manitoba IBD Clinical and Research Centre, 804F-715 McDermot Avenue, Winnipeg, Manitoba, Canada R3E3P4

Wojciech Blonski, MD, PhD  Division of Gastroenterology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland

Russell D. Cohen, MD  AAssociate Professor of Medicine, Pritzker School of Medicine Co-Director, Inflammatory Bowel Disease Center, The University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 4076 Chicago IL, 60637 USA; Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA

Janice C. Colwell, RN, MS, CWOCN  Department of General Surgery, University of Chicago Medical Center, Chicago, IL, USA

Fabio Cominelli, MD, PhD  Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH, USA

Levinus A. Dieleman, MD, PhD  Department of Medicine, Centre of Excellence in GastroIntestinal Inflammation Research, Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada

Marla Dubinsky, MD  Pediatric IBD Center, Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Anders Ekbom, MD, PhD  Department of Medicine, Karolinska Institute, Stockholm, Sweden
Richard N. Fedorak, MD  Centre of Excellence in GastroIntestinal Inflammation Research, Zeidler Family Gastrointestinal Health and Research Centre, Edmonton, AB, Canada

Stephen B. Hanauer, MD  Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Pritzker School of Medicine, Chicago, IL, USA; Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA

Roger Hurst, MD  University of Chicago Pritzker School of Medicine, Chicago, IL, USA; Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA

Sunanda Kane, MD  Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

Joseph B. Kirsner, MD, PhD  University of Chicago Pritzker School of Medicine, Chicago, IL, USA; Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA

David Kotlyar, BS  University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Rebecca Kowalczyk, MD  Mayo Clinic College of Medicine, Rochester, MN, USA

Jonathan A. Leighton, MD  Division of Gastroenterology and Hepatology, Mayo Clinic in Arizona, Scottsdale, AZ, USA

L. Campbell Levy, MD  Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Gary R. Lichtenstein, MD  Division of Gastroenterology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Karen L. Madsen, PhD  Department of Medicine, Centre of Excellence in GastroIntestinal Inflammation Research, Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada

Dana Moffatt, MD  Section of Gastroenterology, University of Manitoba, Winnipeg, MB, Canada

Koenraad J. Mortele, MD  Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Shabana F. Pasha, MD  Division of Gastroenterology and Hepatology, The Mayo Clinic in Arizona, Scottsdale, AZ, USA

Theresa Pizarro, PhD  Department of Pathology, Case Western Reserve Medical School, Cleveland, OH, USA
Jami A. Rothe, MD  University of Chicago Pritzker School of Medicine, Chicago, IL, USA

David T. Rubin, MD  University of Chicago Pritzker School of Medicine, Chicago, IL, USA; Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA

Vikram A. Sahni, MD  Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Ernest G. Seidman, MDCM  Research Institute of McGill University Health Center, Montreal, QC, Canada

Corey A. Siegel, MD  Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Raja Tamaz, MD  Department of Medicine, Division of Gastroenterology, University of Montreal, Montreal, QC, Canada

Nanda Venu, MD  Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA

Christopher R. Weber, MD, PhD  Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA; The University of Chicago Medical Center, Chicago, IL, USA